🇺🇸 FDA
Patent

US 9238799

Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses

granted A61KA61K2039/5254A61K2039/5256

Quick answer

US patent 9238799 (Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jan 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/5254, A61K2039/5256, A61K2039/70, A61K39/12